相似文献
1
Back to basics: PCSK9 as a new target for the LDL receptor.
Arq Bras Cardiol. 2014 Jan;102(1):e5-8. doi: 10.5935/abc.20130248.
2
Inhibition of PCSK9: is this the way forward for managing residual risk?
Curr Opin Lipidol. 2012 Oct;23(5):509-10. doi: 10.1097/MOL.0b013e328358246a.
3
[New drug development competition for LDL receptor].
Nihon Yakurigaku Zasshi. 2014 May;143(5):262. doi: 10.1254/fpj.143.262.
4
Winner by points?--LDL cholesterol as a target for therapeutic intervention.
Curr Opin Lipidol. 2013 Jun;24(3):277-8. doi: 10.1097/MOL.0b013e3283616315.
5
[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23.
6
The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels.
Pharmacogenet Genomics. 2015 Mar;25(3):134-42. doi: 10.1097/FPC.0000000000000120.
7
The PCSK9 decade.
J Lipid Res. 2012 Dec;53(12):2515-24. doi: 10.1194/jlr.R026658. Epub 2012 Jul 17.
8
Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
J Pharmacol Exp Ther. 2012 Feb;340(2):228-36. doi: 10.1124/jpet.111.187419. Epub 2011 Oct 21.
9
Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
Nat Rev Endocrinol. 2013 Feb;9(2):76-8. doi: 10.1038/nrendo.2012.254. Epub 2013 Jan 8.
10
Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1484-93. doi: 10.1161/ATVBAHA.112.300263. Epub 2013 Apr 4.
引用本文的文献
1
New and emerging lipid-modifying drugs to lower LDL cholesterol.
Drugs Context. 2021 Nov 1;10. doi: 10.7573/dic.2021-8-3. eCollection 2021.
2
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Int J Biomed Investig. 2018;1(1). doi: 10.31531/2581-4745.1000106. Epub 2018 Mar 27.
本文引用的文献
1
Proprotein convertase subtilisin/kexin type 9 inhibition.
Curr Opin Lipidol. 2012 Dec;23(6):511-7. doi: 10.1097/MOL.0b013e3283587563.
2
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.
Lancet. 2012 Aug 11;380(9841):572-80. doi: 10.1016/S0140-6736(12)60312-2. Epub 2012 May 17.
3
Proprotein convertases in health and disease.
N Engl J Med. 2011 Dec 29;365(26):2507-18. doi: 10.1056/NEJMra1106700.
4
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Circulation. 2011 May 24;123(20):2292-333. doi: 10.1161/CIR.0b013e3182160726. Epub 2011 Apr 18.
5
The LDL receptor.
Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):431-8. doi: 10.1161/ATVBAHA.108.179564.
6
PCSK9: a convertase that coordinates LDL catabolism.
J Lipid Res. 2009 Apr;50 Suppl(Suppl):S172-7. doi: 10.1194/jlr.R800091-JLR200. Epub 2008 Nov 19.
7
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
N Engl J Med. 2006 Mar 23;354(12):1264-72. doi: 10.1056/NEJMoa054013.
8
Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.
J Am Coll Cardiol. 2004 Jun 2;43(11):2142-6. doi: 10.1016/j.jacc.2004.03.046.
9
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Nat Genet. 2003 Jun;34(2):154-6. doi: 10.1038/ng1161.
10
The discovery and development of HMG-CoA reductase inhibitors.
J Lipid Res. 1992 Nov;33(11):1569-82.
Zotero 插件